As the first high-priced stock on the Growth Enterprise Market, Hongri Pharmaceutical is particularly eye-catching, with a price-earnings ratio as high as 49. 18 t
As the first high-priced stock on the Growth Enterprise Market, Hongri Pharmaceutical is particularly eye-catching, with a price-earnings ratio as high as 49. 18 times the issue price of 60 yuan, and its online subscription winning rate has also reached a record high of 1.0 12%.
GEM's family-style rich characteristics are being vividly displayed in Hongri Pharmaceutical. According to the issue price, as many as five billionaires were directly generated after the listing of Hongri Pharmaceutical, including Li Zhantong, the actual controller of Hongri Pharmaceutical, and Yao Xiaoqing, the chairman and president.
According to the data, Li Zhantong and his concerted actions hold 1400.555438+0000 shares through Datong Investment, accounting for 27.82%, and Yao Xiaoqing directly holds 12809254 shares, accounting for 25.44%. According to the issue price, Yao Xiaoqing's net worth is as high as 770 million yuan, while Li Zhantong and his concerted actions add up to 840 million yuan.
Although Li Zhantong is the actual controller of Hongri Pharmaceutical, Yao Xiaoqing, whose initial shareholding ratio is only14, has a tendency to catch up with others. If calculated by his own shareholding, Yao Xiaoqing's shareholding ratio is higher than that of Li Zhantong. According to the prospectus, Li Zhantong directly holds 70% equity of Chase Investment. According to this conversion, the book wealth of Hongri Pharmaceutical increased by 590 million yuan, lower than that of Yao Xiaoqing, a latecomer.
In addition, Yao Xiaoqing's sister Yao Xiaoping and his brother's spouse Hu hold12,480 shares and 5,200 shares respectively, while the spouse's sister holds 74,880 shares, and Sun Changhai's spouse's sister Shi Xiuyan, the eighth largest shareholder of Hongri Pharmaceutical, holds10,400 shares, all of which are promoted to the new rich class through Hongri Pharmaceutical.